Agonist properties of N,N-dimethyltryptamine at serotonin 5-HT2A and 5-HT2C receptors - PubMed (original) (raw)
Agonist properties of N,N-dimethyltryptamine at serotonin 5-HT2A and 5-HT2C receptors
R L Smith et al. Pharmacol Biochem Behav. 1998 Nov.
Abstract
Extensive behavioral and biochemical evidence suggests an agonist role at the 5-HT2A receptor, and perhaps the 5-HT2C receptor, in the mechanism of action of hallucinogenic drugs. However the published in vitro pharmacological properties of N,N-dimethyltryptamine (DMT), an hallucinogenic tryptamine analog, are not consistent with this hypothesis. We, therefore, undertook an extensive investigation into the properties of DMT at 5-HT2A and 5-HT2C receptors. In fibroblasts transfected with the 5-HT2A receptor or the 5-HT2C receptor, DMT activated the major intracellular signaling pathway (phosphoinositide hydrolysis) to an extent comparable to that produced by serotonin. Because drug efficacy changes with receptor density and cellular microenvironment, we also examined the properties of DMT in native preparations using a behavioral and biochemical approach. Rats were trained to discriminate an antagonist ketanserin from an agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) in a two-lever choice paradigm. Pharmacological studies showed that responding on the DOI and ketanserin lever reflected agonist and antagonist activity at 5-HT2A receptors, and hence, was a suitable model for evaluating the in vivo functional properties of DMT. Like other 5-HT2A receptor agonists, DMT substituted fully for DOI. Intact choroid plexus was used to evaluate the agonist properties at endogenous 5-HT2C receptors; DMT was a partial agonist at 5-HT2C receptors in this native preparation. Thus, we conclude that DMT behaves as an agonist at both 5-HT2A and 5-HT2A receptors. One difference was evident in that the 5-HT2C, but not the 5-HT2A, receptor showed a profound desensitization to DMT over time. This difference is interesting in light of the recent report that the hallucinogenic activity of DMT does not tolerate in humans and suggests the 5-HT2C receptor plays a less prominent role in the action of DMT.
Similar articles
- The role of 5-HT2A, 5-HT 2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice.
Carbonaro TM, Eshleman AJ, Forster MJ, Cheng K, Rice KC, Gatch MB. Carbonaro TM, et al. Psychopharmacology (Berl). 2015 Jan;232(1):275-84. doi: 10.1007/s00213-014-3658-3. Epub 2014 Jul 3. Psychopharmacology (Berl). 2015. PMID: 24985890 Free PMC article. - Characterisation of human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors expressed in the human neuroblastoma cell line SH-SY5Y: comparative stimulation by hallucinogenic drugs.
Newton RA, Phipps SL, Flanigan TP, Newberry NR, Carey JE, Kumar C, McDonald B, Chen C, Elliott JM. Newton RA, et al. J Neurochem. 1996 Dec;67(6):2521-31. doi: 10.1046/j.1471-4159.1996.67062521.x. J Neurochem. 1996. PMID: 8931486 - 1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist.
Nichols DE, Frescas S, Marona-Lewicka D, Huang X, Roth BL, Gudelsky GA, Nash JF. Nichols DE, et al. J Med Chem. 1994 Dec 9;37(25):4346-51. doi: 10.1021/jm00051a011. J Med Chem. 1994. PMID: 7996545 - A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity.
Frecska E, Szabo A, Winkelman MJ, Luna LE, McKenna DJ. Frecska E, et al. J Neural Transm (Vienna). 2013 Sep;120(9):1295-303. doi: 10.1007/s00702-013-1024-y. Epub 2013 Apr 26. J Neural Transm (Vienna). 2013. PMID: 23619992 Review. - Hypothetical biosynthetic pathways of pharmaceutically potential hallucinogenic metabolites in Myristicaceae, mechanistic convergence and co-evolutionary trends in plants and humans.
Barman R, Kumar Bora P, Saikia J, Konwar P, Sarkar A, Kemprai P, Proteem Saikia S, Haldar S, Slater A, Banik D. Barman R, et al. Phytochemistry. 2024 Feb;218:113928. doi: 10.1016/j.phytochem.2023.113928. Epub 2023 Nov 29. Phytochemistry. 2024. PMID: 38035973 Review.
Cited by
- Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans.
Cumming P, Scheidegger M, Dornbierer D, Palner M, Quednow BB, Martin-Soelch C. Cumming P, et al. Molecules. 2021 Apr 22;26(9):2451. doi: 10.3390/molecules26092451. Molecules. 2021. PMID: 33922330 Free PMC article. Review. - Seeing with the eyes shut: neural basis of enhanced imagery following Ayahuasca ingestion.
de Araujo DB, Ribeiro S, Cecchi GA, Carvalho FM, Sanchez TA, Pinto JP, de Martinis BS, Crippa JA, Hallak JE, Santos AC. de Araujo DB, et al. Hum Brain Mapp. 2012 Nov;33(11):2550-60. doi: 10.1002/hbm.21381. Epub 2011 Sep 16. Hum Brain Mapp. 2012. PMID: 21922603 Free PMC article. - Comparison of the discriminative stimulus effects of dimethyltryptamine with different classes of psychoactive compounds in rats.
Gatch MB, Rutledge MA, Carbonaro T, Forster MJ. Gatch MB, et al. Psychopharmacology (Berl). 2009 Jul;204(4):715-24. doi: 10.1007/s00213-009-1501-z. Epub 2009 Mar 14. Psychopharmacology (Berl). 2009. PMID: 19288085 Free PMC article. - Indolethylamine-_N_-methyltransferase Polymorphisms: Genetic and Biochemical Approaches for Study of Endogenous N,N,-dimethyltryptamine.
Dean JG. Dean JG. Front Neurosci. 2018 Apr 23;12:232. doi: 10.3389/fnins.2018.00232. eCollection 2018. Front Neurosci. 2018. PMID: 29740267 Free PMC article. Review. - Hypothesis: The Psychedelic Ayahuasca Heals Traumatic Memories via a Sigma 1 Receptor-Mediated Epigenetic-Mnemonic Process.
Inserra A. Inserra A. Front Pharmacol. 2018 Apr 5;9:330. doi: 10.3389/fphar.2018.00330. eCollection 2018. Front Pharmacol. 2018. PMID: 29674970 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources